Skip to main content
Top
Published in: Insights into Imaging 1/2022

Open Access 01-12-2022 | Adenocarcinoma of the Esophagogastric Junction | Original Article

Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study

Authors: Wenpeng Huang, Liming Li, Siyun Liu, Yunjin Chen, Chenchen Liu, Yijing Han, Fang Wang, Pengchao Zhan, Huiping Zhao, Jing Li, Jianbo Gao

Published in: Insights into Imaging | Issue 1/2022

Login to get access

Abstract

Purpose

This study aimed to develop and validate CT-based models to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) for advanced adenocarcinoma of the esophagogastric junction (AEG).

Methods

Pre-NAC clinical and imaging data of AEG patients who underwent surgical resection after preoperative-NAC at two centers were retrospectively collected from November 2014 to September 2020. The dataset included training (n = 60) and external validation groups (n = 32). Three models, including CT-based radiomics, clinical and radiomics–clinical combined models, were established to differentiate pCR (tumor regression grade (TRG) = grade 0) and nonpCR (TRG = grade 1–3) patients. For the radiomics model, tumor-region-based radiomics features in the arterial and venous phases were extracted and selected. The naïve Bayes classifier was used to establish arterial- and venous-phase radiomics models. The selected candidate clinical factors were used to establish a clinical model, which was further incorporated into the radiomics–clinical combined model. ROC analysis, calibration and decision curves were used to assess the model performance.

Results

For the radiomics model, the AUC values obtained using the venous data were higher than those obtained using the arterial data (training: 0.751 vs. 0.736; validation: 0.768 vs. 0.750). Borrmann typing, tumor thickness and degree of differentiation were utilized to establish the clinical model (AUC-training: 0.753; AUC-validation: 0.848). The combination of arterial- and venous-phase radiomics and clinical factors further improved the discriminatory performance of the model (AUC-training: 0.838; AUC-validation: 0.902). The decision curve reflects the higher net benefit of the combined model.

Conclusion

The combination of CT imaging and clinical factors pre-NAC for advanced AEG could help stratify potential responsiveness to NAC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Manabe N, Matsueda K, Haruma K (2022) epidemiological review of gastroesophageal junction adenocarcinoma in Asian countries. Digestion 103:29–36PubMedCrossRef Manabe N, Matsueda K, Haruma K (2022) epidemiological review of gastroesophageal junction adenocarcinoma in Asian countries. Digestion 103:29–36PubMedCrossRef
2.
go back to reference Coccolini F, Nardi M, Montori G et al (2018) Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer: meta-analysis of randomized trials. Int J Surg 51:120–127PubMedCrossRef Coccolini F, Nardi M, Montori G et al (2018) Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer: meta-analysis of randomized trials. Int J Surg 51:120–127PubMedCrossRef
3.
go back to reference Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721PubMedCrossRef Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721PubMedCrossRef
4.
go back to reference Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393:1948–1957PubMedCrossRef Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393:1948–1957PubMedCrossRef
5.
go back to reference Kano M, Hayano K, Hayashi H et al (2019) Survival benefit of neoadjuvant chemotherapy with S-1 plus docetaxel for locally advanced gastric cancer: a propensity score-matched analysis. Ann Surg Oncol 26:1805–1813PubMedPubMedCentralCrossRef Kano M, Hayano K, Hayashi H et al (2019) Survival benefit of neoadjuvant chemotherapy with S-1 plus docetaxel for locally advanced gastric cancer: a propensity score-matched analysis. Ann Surg Oncol 26:1805–1813PubMedPubMedCentralCrossRef
6.
go back to reference Kodera Y (2017) Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today 47:899–907PubMedCrossRef Kodera Y (2017) Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today 47:899–907PubMedCrossRef
7.
go back to reference D’Ugo D, Persiani R, Rausei S et al (2006) Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol 32:1105–1109PubMedCrossRef D’Ugo D, Persiani R, Rausei S et al (2006) Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol 32:1105–1109PubMedCrossRef
8.
go back to reference Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef
9.
go back to reference Davies AR, Gossage JA, Zylstra J et al (2014) Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol 32:2983–2990PubMedCrossRef Davies AR, Gossage JA, Zylstra J et al (2014) Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol 32:2983–2990PubMedCrossRef
10.
go back to reference Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ (2014) Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One 9:e86941PubMedPubMedCentralCrossRef Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ (2014) Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One 9:e86941PubMedPubMedCentralCrossRef
11.
go back to reference Téoule P, Trojan J, Bechstein W, Woeste G (2015) Impact of neoadjuvant chemotherapy on postoperative morbidity after gastrectomy for gastric cancer. Dig Surg 32:229–237PubMedCrossRef Téoule P, Trojan J, Bechstein W, Woeste G (2015) Impact of neoadjuvant chemotherapy on postoperative morbidity after gastrectomy for gastric cancer. Dig Surg 32:229–237PubMedCrossRef
12.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
13.
go back to reference Liu K, Li G, Fan C, Zhou C, Li J (2012) Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiol 53:127–134PubMedCrossRef Liu K, Li G, Fan C, Zhou C, Li J (2012) Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiol 53:127–134PubMedCrossRef
15.
go back to reference Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21:4604–4610PubMedCrossRef Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21:4604–4610PubMedCrossRef
16.
go back to reference Park S, Ha S, Kwon HW et al (2017) Prospective evaluation of changes in tumor size and tumor metabolism in patients with advanced gastric cancer undergoing chemotherapy: association and clinical implication. J Nucl Med 58:899–904PubMedCrossRef Park S, Ha S, Kwon HW et al (2017) Prospective evaluation of changes in tumor size and tumor metabolism in patients with advanced gastric cancer undergoing chemotherapy: association and clinical implication. J Nucl Med 58:899–904PubMedCrossRef
17.
go back to reference Tang L, Li ZY, Li ZW et al (2015) Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol 70:1198–1204PubMedCrossRef Tang L, Li ZY, Li ZW et al (2015) Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol 70:1198–1204PubMedCrossRef
18.
go back to reference De Cobelli F, Giganti F, Orsenigo E et al (2013) Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur Radiol 23:2165–2174PubMedCrossRef De Cobelli F, Giganti F, Orsenigo E et al (2013) Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur Radiol 23:2165–2174PubMedCrossRef
19.
go back to reference Bhandari A, Ibrahim M, Sharma C, Liong R, Gustafson S, Prior M (2021) CT-based radiomics for differentiating renal tumours: a systematic review. Abdom Radiol (NY) 46:2052–2063CrossRef Bhandari A, Ibrahim M, Sharma C, Liong R, Gustafson S, Prior M (2021) CT-based radiomics for differentiating renal tumours: a systematic review. Abdom Radiol (NY) 46:2052–2063CrossRef
20.
21.
go back to reference Ibrahim A, Primakov S, Beuque M et al (2021) Radiomics for precision medicine: current challenges, future prospects, and the proposal of a new framework. Methods 188:20–29PubMedCrossRef Ibrahim A, Primakov S, Beuque M et al (2021) Radiomics for precision medicine: current challenges, future prospects, and the proposal of a new framework. Methods 188:20–29PubMedCrossRef
23.
go back to reference Kao YS, Hsu Y (2021) A meta-analysis for using radiomics to predict complete pathological response in esophageal cancer patients receiving neoadjuvant chemoradiation. In Vivo 35:1857–1863PubMedPubMedCentralCrossRef Kao YS, Hsu Y (2021) A meta-analysis for using radiomics to predict complete pathological response in esophageal cancer patients receiving neoadjuvant chemoradiation. In Vivo 35:1857–1863PubMedPubMedCentralCrossRef
24.
go back to reference Beukinga RJ, Wang D, Karrenbeld A et al (2021) Addition of HER2 and CD44 to 18F-FDG PET-based clinico-radiomic models enhances prediction of neoadjuvant chemoradiotherapy response in esophageal cancer. Eur Radiol 31:3306–3314PubMedCrossRef Beukinga RJ, Wang D, Karrenbeld A et al (2021) Addition of HER2 and CD44 to 18F-FDG PET-based clinico-radiomic models enhances prediction of neoadjuvant chemoradiotherapy response in esophageal cancer. Eur Radiol 31:3306–3314PubMedCrossRef
25.
go back to reference Hu Y, Xie C, Yang H et al (2020) Assessment of intratumoral and peritumoral computed tomography radiomics for predicting pathological complete response to neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma. JAMA Netw Open 3:e2015927PubMedPubMedCentralCrossRef Hu Y, Xie C, Yang H et al (2020) Assessment of intratumoral and peritumoral computed tomography radiomics for predicting pathological complete response to neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma. JAMA Netw Open 3:e2015927PubMedPubMedCentralCrossRef
27.
go back to reference In H, Solsky I, Palis B et al (2017) Validation of the of the AJCC TNM staging system for gastric cancer using the national cancer database. Ann Surg Oncol 24:3683–3691PubMedCrossRef In H, Solsky I, Palis B et al (2017) Validation of the of the AJCC TNM staging system for gastric cancer using the national cancer database. Ann Surg Oncol 24:3683–3691PubMedCrossRef
28.
go back to reference In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T (2007) Gastric cancer: preoperative local staging with 3D multi-detector row CT–correlation with surgical and histopathologic results. Radiology 242:472–482CrossRef In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T (2007) Gastric cancer: preoperative local staging with 3D multi-detector row CT–correlation with surgical and histopathologic results. Radiology 242:472–482CrossRef
29.
30.
31.
32.
go back to reference Wang L, Zhang Y, Chen Y et al (2021) The performance of a dual-energy CT derived radiomics model in differentiating serosal invasion for advanced gastric cancer patients after neoadjuvant chemotherapy: iodine map combined with 120-kV equivalent mixed images. Front Oncol 10:562945PubMedPubMedCentralCrossRef Wang L, Zhang Y, Chen Y et al (2021) The performance of a dual-energy CT derived radiomics model in differentiating serosal invasion for advanced gastric cancer patients after neoadjuvant chemotherapy: iodine map combined with 120-kV equivalent mixed images. Front Oncol 10:562945PubMedPubMedCentralCrossRef
33.
go back to reference Xiong BH, Cheng Y, Ma L, Zhang CQ (2014) An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest 32:272–284PubMedCrossRef Xiong BH, Cheng Y, Ma L, Zhang CQ (2014) An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest 32:272–284PubMedCrossRef
34.
go back to reference Samalin E, Ychou M (2007) Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts? Curr Opin Oncol 19:384–389PubMedCrossRef Samalin E, Ychou M (2007) Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts? Curr Opin Oncol 19:384–389PubMedCrossRef
35.
go back to reference Gao X, Ma T, Cui J et al (2021) A CT-based radiomics model for prediction of lymph node metastasis in early stage gastric cancer. Acad Radiol 28:e155–e164PubMedCrossRef Gao X, Ma T, Cui J et al (2021) A CT-based radiomics model for prediction of lymph node metastasis in early stage gastric cancer. Acad Radiol 28:e155–e164PubMedCrossRef
36.
go back to reference Hamm CA, Beetz NL, Savic LJ, Penzkofer T (2020) Künstliche intelligenz und radiomics in der MRT-basierten Prostatadiagnostik [Artificial intelligence and radiomics in MRI-based prostate diagnostics]. Radiologe 60:48–55PubMedCrossRef Hamm CA, Beetz NL, Savic LJ, Penzkofer T (2020) Künstliche intelligenz und radiomics in der MRT-basierten Prostatadiagnostik [Artificial intelligence and radiomics in MRI-based prostate diagnostics]. Radiologe 60:48–55PubMedCrossRef
37.
go back to reference Walsh S, de Jong EEC, Timmeren JE et al (2019) Decision support systems in oncology. JCO Clin Cancer Inform 3:1–9PubMedCrossRef Walsh S, de Jong EEC, Timmeren JE et al (2019) Decision support systems in oncology. JCO Clin Cancer Inform 3:1–9PubMedCrossRef
38.
go back to reference Qin Y, Deng Y, Jiang H, Hu N, Song B (2021) Artificial intelligence in the imaging of gastric cancer: current applications and future direction. Front Oncol 11:631686PubMedPubMedCentralCrossRef Qin Y, Deng Y, Jiang H, Hu N, Song B (2021) Artificial intelligence in the imaging of gastric cancer: current applications and future direction. Front Oncol 11:631686PubMedPubMedCentralCrossRef
39.
go back to reference Bi WL, Hosny A, Schabath MB et al (2019) Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin 69:127–157PubMedPubMedCentral Bi WL, Hosny A, Schabath MB et al (2019) Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin 69:127–157PubMedPubMedCentral
40.
go back to reference Chen Y, Wei K, Liu D et al (2021) A machine learning model for predicting a major response to neoadjuvant chemotherapy in advanced gastric cancer. Front Oncol 11:675458PubMedPubMedCentralCrossRef Chen Y, Wei K, Liu D et al (2021) A machine learning model for predicting a major response to neoadjuvant chemotherapy in advanced gastric cancer. Front Oncol 11:675458PubMedPubMedCentralCrossRef
41.
go back to reference Mazzei MA, Di Giacomo L, Bagnacci G et al (2021) Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). Quant Imaging Med Surg 11:2376–2387PubMedPubMedCentralCrossRef Mazzei MA, Di Giacomo L, Bagnacci G et al (2021) Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). Quant Imaging Med Surg 11:2376–2387PubMedPubMedCentralCrossRef
42.
go back to reference Bashir U, Weeks A, Goda JS, Siddique M, Goh V, Cook GJ (2019) Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. Nucl Med Commun 40:611–617PubMedPubMedCentralCrossRef Bashir U, Weeks A, Goda JS, Siddique M, Goh V, Cook GJ (2019) Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. Nucl Med Commun 40:611–617PubMedPubMedCentralCrossRef
43.
go back to reference Jin Y, Xu Y, Li Y, Chen R, Cai W (2021) Integrative radiogenomics approach for risk assessment of postoperative and adjuvant chemotherapy benefits for gastric cancer patients. Front Oncol 11:755271PubMedPubMedCentralCrossRef Jin Y, Xu Y, Li Y, Chen R, Cai W (2021) Integrative radiogenomics approach for risk assessment of postoperative and adjuvant chemotherapy benefits for gastric cancer patients. Front Oncol 11:755271PubMedPubMedCentralCrossRef
44.
go back to reference Braman NM, Etesami M, Prasanna P et al (2017) Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 19:57PubMedPubMedCentralCrossRef Braman NM, Etesami M, Prasanna P et al (2017) Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 19:57PubMedPubMedCentralCrossRef
45.
go back to reference Wang WT, Yang L, Yang ZX et al (2018) Assessment of microvascular invasion of hepatocellular carcinoma with diffusion kurtosis imaging. Radiology 286:571–580PubMedCrossRef Wang WT, Yang L, Yang ZX et al (2018) Assessment of microvascular invasion of hepatocellular carcinoma with diffusion kurtosis imaging. Radiology 286:571–580PubMedCrossRef
46.
go back to reference Mazurowski MA (2015) Radiogenomics: what it is and why it is important. J Am Coll Radiol 12:862–866PubMedCrossRef Mazurowski MA (2015) Radiogenomics: what it is and why it is important. J Am Coll Radiol 12:862–866PubMedCrossRef
Metadata
Title
Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study
Authors
Wenpeng Huang
Liming Li
Siyun Liu
Yunjin Chen
Chenchen Liu
Yijing Han
Fang Wang
Pengchao Zhan
Huiping Zhao
Jing Li
Jianbo Gao
Publication date
01-12-2022
Publisher
Springer Vienna
Published in
Insights into Imaging / Issue 1/2022
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-022-01273-w

Other articles of this Issue 1/2022

Insights into Imaging 1/2022 Go to the issue